THNR — Amplify Weight Loss Drug & Treatment ETF

—
PCX · Health Care · Developed Markets · CIK ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Amplify Weight Loss Drug & Treatment ETF lets investors reach international companies positioned to benefit from advances in weight-management medicines. Before fees and expenses, it aims to match the VettaFi benchmark of the same theme.
No quarterly fundamentals indexed for this ticker.

News headlines (Yahoo Finance, 1h cache)

Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win
2026-10-01 12:48 · Yahoo
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
2026-06-10 16:00 · Yahoo
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
2026-05-19 18:27 · Yahoo
3 Ways to Invest in the Growing GLP-1 Weight Loss Market
2026-04-17 15:20 · Yahoo
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
2026-07-01 12:13 · Yahoo
The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug
2025-12-29 13:46 · Yahoo
Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in
2025-11-24 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.